AbbVie One Step Closer to Interferon-Free Therapy for Hepatitis C
The Editors at Hepatitis Central
February 4, 2014
Print this page
More than 2,300 patients from over 25 countries around the world have participated in the six Phase III trials being conducted by AbbVie to treat genotype 1 Hepatitis C virus infection using a regimen containing ABT-450.
AbbVie completes Phase III trial program for treatment of hepatitis C genotype 1
PBR Staff Writer Published 03 February 2014
AbbVie has completed its Phase III clinical trial program and released results of four additional studies designed to assess its investigational all-oral, interferon-free therapy with and without ribavirin (RBV) in patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.
Continue reading this entire article:
HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.